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a b s t r a c t
Aim: The aim of this review is to describe and analyze indications and results of the use of
SBRT in uterine cervix cancer, reviewing articles published from January 2010 up to August
2017, for any one of the four indications listed:
1 Patient refusal or anatomic impediments to interstitial or intracavitary brachytherapy
(BCT), i.e. SBRT as an “alternative” for BCT;
2 Patients with voluminous tumors, or asymmetric tumors where BCT alone would not
achieve curative doses, i.e. SBRT as a primary adjunct to BCT;
3 Pelvic and para aortic adenopathy where SBRT could be used as a boost, i.e. SBRT as a
primary adjunct to external beam pelvic radiotherapy;
4 Small volume recurrences (postoperative or post radiotherapy), i.e. SBRT for salvage.
Background: Cervix cancer standard treatment involves pelvic irradiation and chemotherapy,
recent advances in irradiation techniques might offer new possible approaches.
Material and methods: Systematic review of the English language literature about Cervix can-
cer, SBRT, published from January 2010 to January 2018 identified through a database search
of PubMed, and Ovid MEDLINE, using pre-defined search phrases.
Results: The results in the literature, in general, demonstrate rather weak efficacy of SBRT.
In this review, we did not find strong evidence to recommend routine SBRT as a primary
treatment for cervico-uterine cancers, i.e. as a replacement for BCT; in highly selected cases
it might be considered useful as salvage therapy for relapsed cervix cancer.
Conclusion: The existing data to not warrant recommending SBRT for the definitive treatment
of cervix cancer, but may have some value in the recurrent/relapsed setting.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
∗ Corresponding author.
E-mail address: mloretoy@yahoo.com (L. Yanez).
1. Background
The technique of radiosurgery (SRS) consists of delivering high
fractional doses of radiation, usually to a small target in a
single fraction, with the aim of submillimetric precision, and
https://doi.org/10.1016/j.rpor.2018.08.005
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the purpose of ablating the tumor without exceeding toler-
ance doses of organs at risk (OAR). SRS was initially developed
for brain tumors and functional disorders, with the deliv-
ery requiring a neuro-navigational stereotactic system. This
intracranial SRS technique eventually lead to the evolution
of stereotactic fractionated body radiotherapy (SBRT) treat-
ments, wherein instead of a single fraction, a “few fractions”
(typically 3–5) are utilized, and frame-based stereotactic nav-
igational approaches are replaced with image, surface, or
fiducial-based navigation.1
Cervix cancer is the 4th most common cancer in women
worldwide.2 In 2017, ESMO published standardized guidelines
for the non-surgical management of cervix cancer.3 These
guidelines recommend pelvic external beam radiotherapy (or
extended fields for high-risk, node positive patients) with
brachytherapy boost in order to achieve a final total dose of
85 to 90 Gy to the Clinical Tumor Volume. Brachytherapy boost
represents the only safe way to deliver such high doses, which
correlate with improved local control and survival. Such high
dose radiotherapy, based on data from several randomized tri-
als, is delivered concomitantly with chemotherapy, usually on
a weekly, low-dose platinoid scaffold.4,5
The typical approach to treating cervix cancer with radio-
therapy involves whole pelvic irradiation to include the lymph
nodes and primary tumor, and sometimes the nodal chain
along the para-aortic region. The most frequent grade 3
acute toxicities during radiochemotherapy are hematologic
and bowel, both of which can be reduced using intensity-
modulated radiotherapy (IMRT). Proton beam therapy, not
commonly employed, carries the potential benefit of reducing
these bowel and hematologic toxicities. Nodal boost irradi-
ation for macroscopic disease is performed when needed.
OARs such as the spinal cord and kidneys are important to
consider whenever extended field radiotherapy and/or nodal
boost is contemplated. Brachytherapy is tailored to boost the
dose to the cervical, paracervical, parametrial, and vaginal dis-
ease, balancing the prescription dose with the tolerance of
surrounding OARs (small bowel, rectum, sigmoid, and blad-
der). When inadequate dosimetric coverage of voluminous
tumors is identified as a potential limitation, the GEC ESTRO
guidelines6 recommend the addition of interstitial brachyther-
apy to increase local control and limit OAR doses.
When the performance of brachytherapy is compromised,
or the patient refuses brachytherapy, or brachytherapy is
unavailable, SBRT boost in lieu of brachytherapy has been
used. Despite promising short-term responses to SBRT, about
20–40% of patients eventually develop local recurrence.7,8
About half of all recurrences from cervical cancer occur in-
field, and sometimes this is managed with pelvic exenteration,
a highly morbid approach.9–12 Another salvage approach is
ablative irradiation with SBRT, which we will analyze in this
article.
2. Material and methods
PubMed Medline and OVID search of articles published in
English from January 2009 to January 2018 was conducted,
using the following search terms: SABRT, SBRT, Cyberknife,
Cervix cancer. All articles, whether review, prospective, ret-
rospective or case reports of treatments delivered with SBRT
for Cervix cancer were searched. We limited our search to the
most recent 8-year period, given that this coincides with the
advent and utilization of chemoradiotherapy as a standard,
having replaced, the older, more inferior radiotherapy alone
standard.
3. Results
We identified 32 published articles, a majority, in the last 5
years. We categorized these into the following groups, based
on SBRT usage intention:
1 Patient refusal or anatomic impediments to interstitial or
intracavitary brachytherapy (BCT), i.e. SBRT as an “alterna-
tive” for BCT;
2 Pelvic and para-aortic adenopathy where SBRT could be
used as a boost, i.e. SBRT as a primary adjunct to external
beam pelvic radiotherapy;
3 Small volume recurrences (postoperative or post radiothe-
rapy), i.e. SBRT for salvage.
1 SBRT as an Alternative to Brachytherapy:
SBRT is not an established or accepted alternative to
BCT. However, in certain patients, BCT is precluded by coex-
isting medical conditions, unfavourable anatomy (too close
to OARs or unfavourable tumor size in terms of achieving
adequate dosimetric coverage; further, some patients occa-
sionally refuse BCT because of its relatively invasive nature.
These patients have historically been treated with conven-
tional or IMRT external beam boost instead of BCT.13,14 In
general, the total curative intent dose achieved with this
approach is lower than that achieved with BCT. For example,
Barraclough et al.,15 delivered 54–70 Gy total dose with EBRT
to patients who had not received BCT. Unfortunately, most of
these patients developed a central recurrence in less than 5
years and had a 5 year overall survival of only 49.3%15; on
the other hand those receiving both pelvic radiotherapy and
BCT had superior 5 year local control and much higher 5 year
survival of about 70%.16,17
In such patients not suitable for brachytherapy, SBRT could
deliver a boost to the cervix, more comparable to that achieved
with BCT; with modern motion-tracking systems, this is
achieved without inordinately large expansion margins for the
planning target volume (PTV).18,19 Another advantage of using
SBRT in this context is the ability to keep the total treatment
time short, since lengthening treatment duration is known to
be deleterious, especially if it extends beyond 7 weeks.20,21
Wan et al.22 performed dosimetric evaluation of HDR BCT
versus SBRT in 40 patients with advanced cervix cancer or
tumors with asymmetric morphology, and demonstrated dosi-
metric comparability; this, however, was only an in silico study
and, therefore, of little clinical utility.
Mahmoud23 performed a literature analysis from 2003 to
2016, to evaluate bioeffect modeling studies comparing BCT
to either conventionally fractionated IMRT as an integrated
boost, or to a hypofractionated SBRT boost. All studies required
at least 5 patients and only 9 articles fulfilled these require-
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Table 1 – SBRT as a boost.




LC % at MFU % of >GII
toxicity
Haas et al. (2012)24 SBRT CK 6 14 50.4/61.2 19.5–20/3–4 fx 100 0
Marnitz et al. (2013)25 SBRT CK 11 6 50.4 30/5 fx 100 0
Kubicek et al. (2013)26 SBRT CK 4 4 45 25/5 fx 75 25
Hsieh et al. (2013)27 SBRT HT 9 36 50.4 16–27/5–9 fx 78 0
Mantz et al. (2016)28 Not reported 30 62 45 40/5 fx 78.6 0
N cervix: number of patients; MFU: median follow-up; WP: whole pelvis; LC: local control.
ments. Five of these 9 (Haas,24 Marnitz25, Kubicek26, Hsieh27,
Mantz28) focused on SBRT boost and were published between
2012 and 2016. This article came to the conclusion that from
a bioeffect modeling perspective, SBRT can emulate BCT, but
once again, these are purely dosimetric and modeling data,
without clinical validation.
We identified 5 clinical reports of the use of SBRT boost
instead of BCT boost after pelvic radiotherapy which in total
contained 60 cervix patients; these reports are summarized in
Table 1. These reports are highlighted below.
In the retrospective series published by Haas et al.,24 six
patients were treated to 45 Gy to the pelvis, plus a conven-
tionally fractionated boost to the cervix and uterus with IMRT
to 50, 4 Gy (in one patient) and 61.2 Gy (in 5 patients); the vol-
ume of the bladder and rectum receiving more than 70 Gy was
limited to < 5% (V70Gy ≤ 5%). After EBRT, patients had 3–4 gold
fiducial markers placed in the cervix and upper vagina. SBRT
planning with thin slice CT scans (1.25 mm) and MR was per-
formed 1 week after fiducial placement with the patient in the
same position as used for the prior pelvic radiotherapy. The
gross tumor volume (GTV) was contoured with CT and MRI.
All patients received SBRT boost using the CyberKnife system;
5 of 6 received 4 Gy × 5, and the other received 6.5 Gy × 3. No
grade 3 or higher rectal or urinary toxicities were reported, but
median follow-up was only 14 months. Five of 6 patients with
at least 12 months follow-up did not experience relapse.
Jorcano et al.14 reported results of 17 endometrial and
9 cervical cancer patients treated with postoperative EBRT
(45–50.4 Gy) followed by an SBRT boost of 14 Gy delivered in
two fractions. With a median follow up of 47 months, the 3-
year loco-regional failure-free and overall survival rates were
96% and 95%, respectively. No severe (>grade-3) acute urinary
or low-gastrointestinal (GI) toxicity was observed during treat-
ment and up to 3 months after treatment completion.
At the 2017 ESTRO meeting, O’Donnell29 reported on a
National Cancer Database review of patients with cervix can-
cer treated from 2004 to 2013 with radiochemotherapy plus
standard BCT boost (n = 14,394) or IMRT (n = 1468) or SBRT boost
(n = 42). After matching patient characteristics, only IMRT had
significantly lower OS than BCT. The median overall survival
was 93.2 months, patients who received BCT boost survived
a median of 99 months, patients with SBRT boost survived
a median of 30.6 months, and patients who received IMRT
boost survived a median of 29.8 months, however, on a multi-
variable analysis, factors significantly associated with poorer
overall survival where: advancing age, having Medicare or
Medicaid insurance, a histology of adenocarcinoma, advanc-
ing FIGO stage of disease (patients with FIGO stage III-IV
disease had poorer survival than early-stage disease), nodal
involvement within the true pelvis, presence of metastatic dis-
ease, and receiving IMRT rather than brachytherapy. In this
article, having an SBRT boost was associated with worse over-
all survival on a univariate analysis (hazard ratio [HR] = 2.222,
95% CI = 1.360Y3.631, p = 0.001) but it was not worse than
brachytherapy on a multivariable Cox proportional hazard
analysis (HR = 1.142, 95% CI = 0.686–1.901, p = 0.609). When
Propensity-Matched Analysis was done in 30 patients who
received SBRT boost with adequate follow-up (matched with
70 control BCT cases) there was no significant difference in
overall survival between those who received SBRT boost and
those who received a brachytherapy boost (HR = 1.477, 95%
CI = 0.746–2.926, p = 0.263).
2 SBRT as treatment for paraaortic lymph node recurrence or
as boost:
There are few cases of SBRT utilization reported in this set-
ting for cervix cancer, we report 2 studies in the literature (30
cervix cancer patients).
Choi et al.30 reported 30 patients with cervix (n = 28) or
endometrial cancer with macroscopic metastatic para aortic
lymph nodes. In 4 cases SBRT was delivered as a complement
to EBRT and in 26 SBRT was used exclusively, obtaining 67%
local control and 50% OS at 4 years follow up. Only 1 patient
developed a late toxicity, 20 months after completion of treat-
ment, a ureteral stricture treated with catheter insertion.
Higginson et al.31 described a series of 7 patients treated
with salvage SBRT for lymph node recurrences in gyneco-
logic cancers, 2 with cervix cancer with macroscopic disease
in pelvic and paraaortic areas, where SBRT boost was used.
With 18 months median follow-up for the cohort of 7 patients,
the rates of one-year loco-regional control, distant failure and
overall survival were 79%, 43%, and 50%, respectively.
3 SBRT for salvage:
The local recurrence rate for cervix cancer is 10–20%
for early stage disease treated with surgery, or definitive
chemotherapy plus radiotherapy with BCT; the recurrence
rates increase to 15% for stages IB and IIA and to 20–50%
for stages II–III. Conventional treatment used for isolated,
non-metastatic, small-volume, central recurrence includes
systemic treatment and pelvic exenteration if the patient was
previously irradiated. Radical radiotherapy is performed when
the first treatment was solely surgery.
Many investigators have reported that lateral recurrences
in the pelvis have worse prognosis than central ones.32–34 This
is probably due to the fact that lateral tumors cause symptoms
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Park et al. (2015)35 68 Cervix 39/3 79% at 5 years 58% at 2 years 5/GIII
Deodato et al. (2009)36 6 All Gyn 20–30/4–6 92% at 1 year NR (PFS 2 year:81, 8%) 0/>GII
Yazici et al. (2013)37 16 Cervix 15–40/3–5 94% at 1 year 60% at 1 year 6/>GIII
Dewas et al (2011)38 16 Gyn + Gi + bladder 36/6 51% at 1 year median OS 11 months 0/>GIII
Abusaris et al (2012)39 27 Cervix + other 16–45/2–6 53% at 2 years NR 0/>GIII
Kunos et al (2012)40 16 All Gyn 24/3 fx 100% at 6 months median OS 20 months 0/>GIII
Choi et al. (2009)30 30 Uterus + cervix 67% at 4 years 50% at 4 years 1/GIII
Seo et al. (2016)41 23 Uterus + cervix 27–45/3 65% at 2 years 43% at 2 years 3 recto vaginal fistulae
later than central recurrences; another reason is that the later-
ally located lymphatic network is more extensive, resulting in
greater microscopic tumor cell dissemination, causing larger
volume recurrences. As a result, there is also a higher risk of
distant relapse. When considering BCT as a treatment, it can
be very difficult to escalate doses in the lateral areas of the
pelvis. It is in these situations that SBRT emerges as an option.
In Table 2, we summarize 8 reports (most of them
cervix + other primary tumors) from the literature describing
a total of 202 cervix patients who were treated with SBRT for
pelvic recurrence.
Seo et al.41 described 23 cervix cancer patients with local
pelvic wall recurrences treated with 27–45 Gy SBRT in 3 frac-
tions of 9–15 Gy. The two-year rates of overall survival, local
progression-free survival, and disease-free survival were 43,
65, and 52%; best results were achieved when the GTV was
<30 cm3. Since this is primarily a palliative treatment, symp-
tom resolution/improvement is also an important endpoint.
Pain control was reported in 13%, and a reduction in pain
medications was achieved in 70% of patients.
Gukenberger42 analyzed the outcomes of 19 previously
treated patients with locally recurrent disease: 12 cervix, and
7 endometrial cancer patients. Sixteen of these patients were
treated with whole pelvic irradiation to 50 Gy plus boost.
Because of large volume of recurrent cancer (median 4.5 cm)
and peripheral location (n = 12), stereotactic body radiotherapy
(SBRT; median 3 fractions of 5 Gy each to 65%) was used for
local dose escalation instead of (n = 16) or combined with (n = 3)
vaginal brachytherapy. Median EQD2 to the recurrent tumor
was 68.8 Gy (range 40–75 Gy) considering the conventionally
fractionated and the dose at the PTV margin of the SBRT boost.
If the dose at the isocenter of the SBRT boost is considered
as treatment dose, median EQD2 to the recurrent tumor was
82.8 Gy (range 62.2–93.8 Gy). Median follow up was 22 months,
median OS was 25 months, and 3-year overall survival was 34%
with systemic progression as the leading cause of death (7 died
of systemic progression, 1 died of local tumor progression, 1
of comorbidities and 1 of unknown cause). The 3-year local
control rate was 81%. G3-G4 late toxicity rate was observed in
3 patients, 2 suffered from grade IV intestino-vaginal fistula
(sigmoidovaginal n = 1; recto-vaginal n = 1) at 16 and 23 months
after salvage radiotherapy. One patient suffered from a grade
IV small bowel ileus, six months after treatment. This resulted
in a 25% rate of late toxicity >grade II at three years. Simi-
lar data have been published in the literature using non-3D
image guided BCT ± EBRT for recurrent gynaecological malig-
nancies (late toxicity >grade II in about 20% of the cases).
This experience suggests that SBRT for local dose escalation
to the residual tumor after conventionally fractionated radio-
therapy of the whole pelvis can result in high rates of local
control in bad prognosis recurrent patients whenever vagi-
nal brachytherapy alone is inappropriate for boost irradiation,
but is also associated with high rates of >grade II late toxici-
ties.
4. Discussion
Therefore, there is clearly a paucity of adequate data that
would support routine substituting BCT for SBRT, and its rou-
tine utilization should not be encouraged. A US SEER database
analysis from 1998 to 2009 showed that there was a tendency
to reduce the use of BCT in cervix cancer.25,27,29 This anal-
ysis identified that IMRT or SBRT in lieu of RCT was used
mostly for older patients, larger tumor size, stage IVA disease,
at treatment centers with a low volume of patients, and at
centers with limited facilities. As expected, the use of IMRT or
SBRT boost was associated with a higher risk of death, even
surpassing the impact of not being able to receive chemother-
apy (concurrent with radiotherapy). In an editorial by Eiffel
et al.16,32 worrisome comments were made about the SEER
database results reporting the reduced use of BCT, since it
has an irreplaceable role in the treatment27 of these patients
with curative potential, and it should clearly not be omitted
or replaced by IMRT or SBRT boost, except for very exceptional
cases, and even here, one must be ready to accept a probable
detriment in outcome.
There are no prospective trials of SBRT in these sett-
ings, and no dose-prescription standardization exists. Most
of the reports in the literature represent anecdotal usage in
small series of patients, either because of patient refusal of
brachytherapy, or because brachytherapy was too challenging
due to location and/or anatomy, or the patients were too frail
to undergo brachytherapy.
The situations in which43,44 SBRT is used in lieu of BCT as
definitive boost are very sparse, and although some so-called
promising results are concluded by the authors, long-term
efficacy and toxicity remain largely unreported.
In the setting of pelvic sidewall recurrence, limited data
suggesting modest efficacy have been reported in the litera-
ture, but clearly, it must be borne in mind that only a select
subset of patients with small volume recurrences can be man-
aged in this manner, as a large dose per fraction associated
with SBRT would likely be too detrimental for patients with
large volume recurrences.
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Finally, in the setting of macroscopic adenopathy, espe-
cially high-pelvic and paraaortic, where BCT is impossible to
perform, SBRT might represent a potential approach.30,31
5. Conclusion
SBRT is not a replacement or an alternative technology for
the management of cervical cancer; technologically and bio-
logically, there is some appeal because of precise delivery, the
ability to overcome the impact of motion, and the ability to
deliver the total dose in a short schedule to achieve biological
comparison to BCT. The literature on this topic is exceedingly
sparse; a handful of dosimetric and modeling studies provide
limited data and information; the clinical reports are mostly
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